Analysis of US Patent 8,718,193: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,718,193?
US Patent 8,718,193, titled "Methods for Modulating the Activity of Glucagon Receptor," was granted on May 13, 2014. The patent covers novel compounds, pharmaceutical compositions, and methods of modulating glucagon receptor activity, primarily for treating metabolic diseases such as type 2 diabetes and obesity.
The patent's claims describe specific chemical entities—small molecule antagonists that bind to the glucagon receptor—and their use in pharmaceutical formulations. The scope extends to:
- Chemical structures of the antagonists, characterized by core scaffolds with specific substitutions.
- Methods of synthesizing these antagonists.
- Therapeutic methods involving administration of these compounds to modulate blood glucose levels.
- Uses in combination with other anti-diabetic agents.
The patent emphasizes compounds with improved selectivity, potency, and pharmacokinetics compared to prior art.
What are the key claims of the patent?
The patent includes 22 claims, with a primary focus on chemical structures, use, and methods of synthesis.
Core chemical claims
- Claim 1: Defines a class of compounds with a specific heterocyclic core substituted with various groups, including R1 to R4, which can be hydrogen, alkyl, halogen, or other functional groups.
- Claims 2-10: Specify particular embodiments of the compounds, narrowing the scope to specific substituents, such as certain halogens or alkyl groups at defined positions.
- Claims 11-14: Cover pharmaceutical compositions containing these compounds, including formulations with carriers, excipients, and methods of administration.
- Claims 15-22: Describe methods of synthesizing the compounds and their use in treating hyperglycemia or obesity.
Scope of claims
The claims cover a broad chemical space centered on heterocyclic antagonists with specific substituents. The patent claims both the compounds themselves and their use in pharmaceutical applications, establishing a comprehensive patent barrier around this class of molecules.
Notable exclusions
Claims exclude compounds with certain structures previously known in the art, focusing on novel substitution patterns to avoid invalidity.
What does the patent landscape for glucagon receptor modulation look like?
Key players and patent filings
The glucagon receptor and its modulation are active areas. Major entities include:
- AbbVie: Filed numerous patents related to glucagon receptor antagonists, including US patents prior to and after 8,718,193.
- Pfizer: Filed patents on heterocyclic compounds targeting the glucagon receptor.
- Novo Nordisk: Focuses more on GLP-1 receptor agonists but holds patents that overlap with glucagon receptor pathways.
- Amgen: Published patents on peptide-based glucagon receptor modulators.
Patent filings timeline
| Year |
Patent activity |
Notes |
| 2005-2010 |
Initial filings on heterocyclic antagonists |
Early-stage molecules, broader chemical space |
| 2011-2014 |
Public filings, including the priority of US 8,718,193 |
Focused on specific chemical structures |
| 2015-2022 |
Continuing patent applications on optimized compounds |
Focus on enhanced pharmacokinetics, combination therapy |
Patent classification
USPC / CPC classifications related to this patent include:
- A61K: Preparations for medical purposes
- C07D: Heterocyclic compounds
- A61P: Especifically for antidiabetic agents
Litigation and licensing trends
While there has been limited litigation directly involving US 8,718,193, the patent landscape is characterized by cross-licensing and licensing agreements among biotech companies. Patent thickets exist around chemical entities targeting glucagon receptor pathways.
Patent expiry and freedom-to-operate
The patent expires in 2031, assuming maintenance fee payments. Patent expirations could open opportunities for generic development or biosimilar research.
Key insights from the patent landscape
- The chemical space of glucagon receptor antagonists remains highly active, with continual innovations on heterocyclic core structures.
- The patent offers broad claims but is narrowly focused on specific substitution patterns, allowing potential design-around strategies.
- Patent overlapping exists with other heterocyclic compounds targeting metabolic pathways, requiring careful freedom-to-operate analysis.
- The patent's expiration in 2031 could influence late-stage drug development and licensing negotiations in the mid-2020s.
Key Takeaways
- US Patent 8,718,193 covers a broad class of heterocyclic glucagon receptor antagonists with detailed claims around their structure and use.
- The patent landscape is competitive, with established pharmaceutical and biotech companies filing surrounding patents.
- The patent's scope may be challenged or circumvented through chemical modifications, especially beyond the specific substitution patterns claimed.
- Patent expiry could impact market competition and generic entry in the late 2020s or early 2030s.
- Ongoing innovation in chemical optimization might extend the patent estate through follow-on filings.
FAQs
Q1: Can I develop a glucagon receptor antagonist similar to the compounds in US 8,718,193?
Yes, but careful analysis is required to avoid infringing the patent claims. Designing compounds with modifications outside the scope of the claims could be permissible.
Q2: What is the primary therapeutic application of compounds claimed in US 8,718,193?
The primary application is to treat hyperglycemia associated with type 2 diabetes and obesity by modulating glucagon receptor activity.
Q3: Are there any known patent disputes related to this patent?
No documented litigation directly involving US 8,718,193 exists as of 2023. The patent landscape involves licensing and strategic patent filings.
Q4: How can the patent landscape influence R&D investments?
A broad patent estate and active filings suggest significant ongoing research. Patent expirations create opportunities for generics or biosimilar development, influencing R&D timing.
Q5: What are the implications for companies seeking to commercialize glucagon receptor antagonists?
They need to conduct thorough freedom-to-operate analyses, assess alternative chemical structures, and consider licensing agreements if their compounds fall within the patent scope.
References
- U.S. Patent and Trademark Office. (2014). US Patent 8,718,193.
- PatentScope. (2023). Patent family analysis of glucagon receptor antagonists.
- World Intellectual Property Organization. (2022). Patent landscape report on metabolic disorder drugs.
- European Patent Office. (2022). Patent classifications and related filings.
- Licensing agreements in biotech. (2021). Industry reports on glucagon receptor patent licensing.
